Santhera Pharmaceuticals Holding AG (Santhera Pharmaceuticals Holding AG) Interest Expense : $-21.61 Mil (TTM As of Jun. 2023)

View and export this data going back to 2008. Start your Free Trial

What is Santhera Pharmaceuticals Holding AG Interest Expense?

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. Santhera Pharmaceuticals Holding AG's interest expense for the six months ended in Jun. 2023 was $ -8.90 Mil. Its interest expense for the trailing twelve months (TTM) ended in Jun. 2023 was $-21.61 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. Santhera Pharmaceuticals Holding AG's Operating Income for the six months ended in Jun. 2023 was $ -22.55 Mil. Santhera Pharmaceuticals Holding AG's Interest Expense for the six months ended in Jun. 2023 was $ -8.90 Mil. Santhera Pharmaceuticals Holding AG did not have earnings to cover the interest expense. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Santhera Pharmaceuticals Holding AG Interest Expense Historical Data

The historical data trend for Santhera Pharmaceuticals Holding AG's Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Santhera Pharmaceuticals Holding AG Interest Expense Chart

Santhera Pharmaceuticals Holding AG Annual Data

Trend

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Interest Expense

Get a 7-Day Free Trial

-4.54

-6.19

-7.76

-17.83

-21.67

Santhera Pharmaceuticals Holding AG Semi-Annual Data
	Dec13	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23
Interest Expense	Get a 7-Day Free Trial															-12.07	-5.93	-8.61	-12.70	-8.90

Santhera Pharmaceuticals Holding AG Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Jun. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was $-21.61 Mil.

Santhera Pharmaceuticals Holding AG (OTCPK:SPHDF) Interest Expense Explanation

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Santhera Pharmaceuticals Holding AG's Interest Expense for the six months ended in Jun. 2023 was $-8.90 Mil. Its Operating Income for the six months ended in Jun. 2023 was $-22.55 Mil. And its Long-Term Debt & Capital Lease Obligation for the six months ended in Jun. 2023 was $21.68 Mil.

Santhera Pharmaceuticals Holding AG's Interest Coverage for the quarter that ended in Jun. 2023 is calculated as

Santhera Pharmaceuticals Holding AG did not have earnings to cover the interest expense.

The higher the ratio, the stronger the company's financial strength is.

Santhera Pharmaceuticals Holding AG (Santhera Pharmaceuticals Holding AG) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Santhera Pharmaceuticals Holding AG (OTCPK:SPHDF) » Definitions » Interest Expense

Comparable Companies

Traded in Other Exchanges

SANNz:UK SANN:Switzerland

Address

Hohenrainstrasse 24, Pratteln, CHE, 4133

Website

https://www.santhera.com

Santhera Pharmaceuticals Holding AG is a specialty pharmaceutical company focused on the development and commercialization of products for the treatment of mitochondrial and neuromuscular diseases, an area that includes many orphan and niche indications with high unmet medical needs. It has one operating segment, namely the development and commercialization of products for the treatment of neuro-ophthalmological, pulmonary, and neuromuscular diseases. The company derives most of its revenue from the European Union.